CRISPR Therapeutics is a gene-editing company that co-developed Casgevy with Vertex. Its clinical pipeline includes in vivo editing programs for cardiovascular targets…
Moderna develops mRNA medicines and markets vaccines against COVID-19 and RSV. With Merck, it is developing intismeran autogene, an individualized neoantigen mRNA…
Illumina makes DNA sequencing instruments, reagents and software used widely in research and clinical genomics. It acquired GRAIL in 2021 and separated…
Recursion describes itself as a clinical-stage 'TechBio' company that combines automated biology and machine learning to find drug candidates. Its most advanced…
GRAIL develops blood tests for early cancer detection; its Galleri multi-cancer early detection test is sold in the U.S. as a laboratory-developed…
Cancer FrontiersCancer is more than 100 diseases, and whether one can be cured depends on its type, its stage and the treatments that can reach it. Here is what doctors mean by cure, remission and “no evidence of disease.”
Cancer FrontiersTargeted drugs, checkpoint inhibitors, CAR-T cells and biomarker testing have joined surgery, radiation and chemotherapy. Each works differently, helps some patients dramatically and others not at all.
AI + MedicineIn breast screening, AI support has been tested in a randomized trial of more than 100,000 women and a real-world study of 460,000. The results are promising, but false alarms, overdiagnosis and deskilling still matter.
BreakthroughsKilling diseased cells in a dish is the easy part of drug development. This guide explains the evidence ladder, why most candidates fail, and seven questions to ask before believing a breakthrough headline.
Genome + CellsFrom the $3 billion Human Genome Project to routine sequencing, reading DNA has become easy. Here is what a genome can reveal today, and where uncertain variants, risk scores and missing context set hard limits.
DeepTech + MedTechOrganoids and organ-on-a-chip systems let researchers test drugs on human tissue models before people. The early evidence is promising but specific, and the models still miss much of real human biology.
Companies + StocksMost medical products begin as university research, then pass through tech transfer offices, licences or spinouts, and the regulatory system. This guide maps each step and the reasons discoveries stall.